Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275538 | 0.81 | MEN1 (0.44) | OPRD1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL20129638 | 0.80 | DUT (0.30) | — | |
| SCHEMBL27402701 | 0.74 | MEN1 (0.51) | OPRD1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL8051571 | 0.74 | MEN1 (0.47) | OPRD1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL20133585 | 0.74 | PLD1 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13701479 | 0.73 | GLS (0.42) | — | |
| SCHEMBL30790940 | 0.72 | HTT (0.32) | — | |
| SCHEMBL4153281 | 0.71 | MEN1 (0.53) | OPRD1MEN1KMT2ASLC6A3 | |
| SCHEMBL4153276 | 0.71 | MEN1 (0.53) | OPRD1MEN1KMT2ASLC6A3 | |
| SCHEMBL31484614 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | OPRD1 229/4885MEN1 3119/4885KMT2A 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.